Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radioactive beads take aim at untreatable liver tumors

NCT ID NCT05953337

Disease control Sponsor: ABK Biomedical Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a treatment called Eye90 microspheres for people with liver cancer that cannot be removed by surgery. The microspheres are tiny glass beads containing radioactive yttrium-90, which are injected into the liver's blood vessels to deliver radiation directly to tumors. The goal is to shrink the tumors and control the cancer. About 120 participants will be enrolled to see how well the treatment works and how safe it is.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Yttrium-90 (Y-90) glass microspheres (Eye90)
What this could lead to
If it works, this could offer a new, effective way to shrink liver tumors and control the disease in patients who cannot have surgery.
What could go wrong
This is an early-stage study with only 120 participants, so results may not apply to everyone. The treatment involves radiation, which can cause side effects like fatigue or liver damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2023

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Must have a confirmed diagnosis of HCC by imaging confirmation with Liver Imaging Reporting and Data System (LIRADS) category 5 or confirmation of HCC via biopsy. * No extra hepatic disease. * Up to 3 lesions with at least one lesion ≥ 2 cm in diameter (long axis) measurable by computed tomography (CT), CBCT, or MRI. At least one lesion must be identified as a target lesion as defined by mRECIST. * Maximal single lesion size of ≤ 8 cm and sum of the maximal tumor dimensions of ≤ 12 cm with the entire tumor burden expected to be treatable within the perfused volume. * Intent to treat all lesions within a single session. * Hypervascular on CBCT, CT, or MRI. * Evidence that \> 33% of the total liver volume is disease-free and will be spared Eye90 treatment. * Life expectancy of ≥ 6 months. * ≥ 18 years old at the time of informed consent Exclusion Criteria: * Platelet count \<50,000/microliter or prothrombin (PT) activity \> 50% normal. * Hemoglobin ≤ 8.5 g/dL (subjects that are non-responders to transfusion or medical management must be excluded). * INR \> 1.7 (if anticoagulated, reversal must be achieved prior to any angiographic procedures). * ALT \> 5x upper limit. * AST \> 5x upper limit. * Bilirubin ≥ 2.0 mg/dL. * eGFR ≤ 50 mL/min/BSA. * Macrovascular invasion. * Incompetent biliary duct system, prior biliary intervention, or a compromised Ampulla of Vater. * Estimated lung dose \> 30 Gy as calculated using the lung shunt fraction and partition model.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma liver cancer liver disorder Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma Hepatocellular carcinoma non-resectable Liver cancer

Contacts and locations

Locations

  • AdventHealth Radiation Oncology at Altamonte Springs

    Altamonte Springs, Florida, 32701, United States

  • Beth Israel Deaconess

    Boston, Massachusetts, 02215, United States

  • Charlotte Radiology

    Charlotte, North Carolina, 28202, United States

  • Emory University Hospital Midtown

    Atlanta, Georgia, 30308, United States

  • Froedtert Hospital/Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • HCA Healthcare Research Institute (Sarah Cannon)

    Nashville, Tennessee, 37203, United States

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • Inland Imaging

    Spokane, Washington, 99203, United States

  • Miami Cardiac and Vascular Institute at Baptist Hospital Miami

    Miami, Florida, 33176, United States

  • Northwestern University Memorial Hospital

    Chicago, Illinois, 60611, United States

  • Ochsner Clinic Foundation

    New Orleans, Louisiana, 70121, United States

  • Piedmont Hospital

    Atlanta, Georgia, 30309, United States

  • SSM Health Saint Louis University

    St Louis, Missouri, 63104, United States

  • The University of Arizona Cancer Center

    Tucson, Arizona, 85719, United States

  • University of California - Irvine

    Orange, California, 92867, United States

  • University of Illinois Hospital and Health Sciences System

    Chicago, Illinois, 60612, United States

  • University of Iowa Health Care

    Iowa City, Iowa, 52242, United States

  • University of Louisville

    Louisville, Kentucky, 40202, United States

  • University of Missouri - Ellis Fischel Cancer Center

    Columbia, Missouri, 65212, United States

  • University of Utah

    Salt Lake City, Utah, 84112, United States

  • Vancouver Coastal Health Research Institution (VCHRI)

    Vancouver, British Columbia, V5Z 1M9, Canada

  • Weill Cornell Medicine-New York Presbyterian Hospital

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.